Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy

Abstract

Purpose. To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment. Methods. We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye. Results. Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision. Conclusion. Intravitreal bevacizumab and triamcinolone could be viable options to treat cystoid macular oedema due to chronic myeloid leukaemia and imatinib therapy.

Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review

“…In a case involving another antitumor agent, imatinib, CME associated with chronic myeloid leukemia and imatinib was treated with intravitreal injection of bevacizumab and triamcinolone [ 17 ]. Since injection of bevacizumab, an anti-VEGF agent, is used to treat CME, bevacizumab treatment for breast cancer might have reduced the degree of paclitaxel-induced CME.…”

Reduced vision in a diabetic patient due to incidental leukaemic retinopathy

“…Alternatively, anti‐vascular endothelial growth factor intravitreal injections such as bevacizumab have been shown to reduce macular oedema in this subgroup of patients . Finally, oral acetazolamide has been used in the treatment of leukaemia‐related macular oedema with good results while being on the medication, but with quick recurrence once off it .…”